Keefe, Bruyette & Woods upgraded shares of HIVE Blockchain Technologies (CVE:HIV – Free Report) to a moderate buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.
Several other research firms have also recently weighed in on HIV. Roth Capital raised HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Wednesday, December 18th. Cantor Fitzgerald raised shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, Northland Capmk upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a strong buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Strong Buy”.
Get Our Latest Report on HIVE Blockchain Technologies
HIVE Blockchain Technologies Stock Performance
Featured Articles
- Five stocks we like better than HIVE Blockchain Technologies
- What does consumer price index measure?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Upcoming IPO Stock Lockup Period, Explained
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
